Historical ew News Stories

Edwards Lifesciences: Q4 Beat, EU Win; Shares Surge

Edwards Lifesciences (EW) saw a notable stock uptick after a stronger-than-expected Q4 revenue print, lifted guidance for 2026, and resolved an EU antitrust probe by removing its anti-copycat policy. Key drivers: robust TAVR performance, rapid TMTT growth, FDA approval of SAPIEN M3, and disciplined capital returns.

Edwards Lifesciences Gains After Q4 Results Rally!

Edwards Lifesciences (EW) climbed after Q4 results showed revenue slightly above estimates despite an EPS miss. Elevated trading volume, a premium valuation, and upbeat guidance underpin analyst optimism and investor interest in this S&P 500 medtech name.

Edwards Lifesciences: Q4 Beat Sparks Volatility

Edwards Lifesciences reported mixed Q4 results with strong revenue growth driven by TAVR and TMTT products, an EPS miss, and a bullish 2026 outlook. The stock showed sharp post-earnings swings as investors weighed near-term investment plans against long-term growth guidance. Key drivers to monitor include TAVR reimbursement progress, execution on TMTT expansion, and trading volume signaling institutional positioning.

Edwards Lifesciences: Volume Spike Drives Pullback.

Edwards Lifesciences (EW) experienced elevated trading volume and several days of share-price decline in early February 2026, underperforming peers despite solid fundamentals and recent product approvals. Key drivers include heightened investor rebalancing, the commercial ramp of SAPIEN M3, and upcoming clinical data and guidance milestones.